Literature DB >> 17228055

The impact of central obesity as a prerequisite for the diagnosis of metabolic syndrome.

Chin Meng Khoo1, Choon Fong Liew, Suok Kai Chew, E Shyong Tai.   

Abstract

OBJECTIVE: To compare the prevalence of metabolic syndrome (MS) defined according to the American Heart Association (AHA)/National Heart Lung and Blood Institute (NHLBI) and the International Diabetes Federation (IDF) and to determine the effect of the presence of central obesity on the phenotype (insulin resistance and other cardiovascular risk factors) associated with MS. RESEARCH METHODS AND PROCEDURES: We studied 4723 Chinese, Malays, and Asian Indians living in Singapore. Each individual was categorized according to the five criteria for MS as defined by the AHA/NHLBI and the IDF. The population was categorized according to the presence of three or more criteria and then further subcategorized according to the presence or absence of central obesity. Characteristics of each group were compared using ANOVA and the chi2 test.
RESULTS: MS was present in 20.2% (IDF) and 26.9% (AHA/NHLBI) of the population. Of the population, 6.7% exhibited three or more features of MS without central obesity. Use of the IDF definition, which requires central obesity, is associated with greater insulin resistance but similar levels of other cardiovascular disease risk factors than the use of the AHA/NHLBI definition, which does not require central obesity. DISCUSSION: In this Southeast Asian population, the IDF and the AHA/NHLBI definitions of MS identify different segments of the MS population. The IDF definition may be more appropriate for the identification of those with insulin resistance and increased risk of type 2 diabetes. In contrast, the AHA/NHLBI definition may better identify those at increased risk of cardiovascular disease.

Entities:  

Mesh:

Year:  2007        PMID: 17228055     DOI: 10.1038/oby.2007.559

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  6 in total

1.  Metabolic syndrome and its effect on the outcomes of rheumatoid arthritis in a multi-ethnic cohort in Singapore.

Authors:  Jia Yi Hee; Melinda M Protani; Ee Tzun Koh; Khai Pang Leong
Journal:  Clin Rheumatol       Date:  2021-10-15       Impact factor: 2.980

2.  The relation of metabolic syndrome according to five definitions to cardiovascular risk factors--a population-based study.

Authors:  Cheng-Chieh Lin; Chiu-Shong Liu; Chia-Ing Li; Wen-Yuan Lin; Ming-May Lai; Tsann Lin; Pei-Chia Chang; Yih-Dar Lee; Ching-Chu Chen; Chih-Hsueh Lin; Chuan-Wei Yang; Chih-Yi Hsiao; Walter Chen; Tsai-Chung Li
Journal:  BMC Public Health       Date:  2009-12-23       Impact factor: 3.295

3.  Determinants of Health-Related Quality of Life (HRQoL) in the Multiethnic Singapore Population - A National Cohort Study.

Authors:  Melvin Khee-Shing Leow; Konstadina Griva; Robin Choo; Hwee-Lin Wee; Julian Thumboo; E Shyong Tai; Stanton Newman
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

4.  JIS definition identified more Malaysian adults with metabolic syndrome compared to the NCEP-ATP III and IDF criteria.

Authors:  Anis Safura Ramli; Aqil Mohammad Daher; Mohamed Noor Khan Nor-Ashikin; Nafiza Mat-Nasir; Kien Keat Ng; Maizatullifah Miskan; Krishnapillai S Ambigga; Farnaza Ariffin; Md Yasin Mazapuspavina; Suraya Abdul-Razak; Hasidah Abdul-Hamid; Fadhlina Abd-Majid; Najmin Abu-Bakar; Hapizah Nawawi; Khalid Yusoff
Journal:  Biomed Res Int       Date:  2013-09-23       Impact factor: 3.411

Review 5.  Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review.

Authors:  P Ranasinghe; Y Mathangasinghe; R Jayawardena; A P Hills; A Misra
Journal:  BMC Public Health       Date:  2017-01-21       Impact factor: 3.295

6.  Analysis of agreement among definitions of metabolic syndrome in nondiabetic Turkish adults: a methodological study.

Authors:  Ahmet Selcuk Can; Thomas P Bersot
Journal:  BMC Public Health       Date:  2007-12-19       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.